🔥 Premium AI-powered Stock Picks from InvestingPro Now up to 50% OffCLAIM SALE

TFF Pharmaceuticals announces $4.8 million stock offering

Published 04/30/2024, 08:22 AM

FORT WORTH, Texas - TFF Pharmaceuticals, Inc. (NASDAQ:TFFP), a clinical-stage biopharmaceutical company, has launched a public offering of shares and warrants, expecting to raise approximately $4.8 million in gross proceeds. The offering includes 1,665,219 shares of common stock or equivalents and warrants to purchase an equal number of shares. The combined public offering price is set at $2.875 per share and accompanying warrant.

The warrants, exercisable immediately upon issuance at $2.75 per share, will expire five years from the date of issuance. The expected closing date of the offering is May 1, 2024, contingent upon meeting customary closing conditions. H.C. Wainwright & Co. serves as the exclusive placement agent for the offering.

TFF Pharmaceuticals intends to allocate the net proceeds for working capital and general corporate purposes. The offering is conducted under a registration statement on Form S-1, declared effective by the Securities and Exchange Commission (SEC) on April 29, 2024.

The company specializes in developing dry powder formulations of medicines through its patented Thin Film Freezing (TFF) technology, which is applicable to a wide range of drugs, including vaccines and biologics. This technology aims to enhance the efficacy, safety, and stability of medications.

InvestingPro Insights

In light of TFF Pharmaceuticals' recent public offering, investors may find the following insights from InvestingPro valuable for making informed decisions. The company's market capitalization stands at a modest $6.93 million, reflecting the size and current valuation in the market. Despite a significant revenue growth rate of 48.02% in the last twelve months as of Q4 2023, it's important to note that TFF Pharmaceuticals has a negative gross profit margin of -1531.39% for the same period, indicating substantial costs outweighing revenue.

InvestingPro Tips suggest that TFFP's stock is currently in oversold territory, which could potentially interest value investors looking for a rebound opportunity. However, it's crucial to consider that the company is not only quickly burning through cash but also has experienced substantial price declines, with a one-month total return of -55.13% as of the most recent data point. This could indicate a bearish sentiment among investors or a response to broader market conditions.

For those considering an investment in TFF Pharmaceuticals, there are additional InvestingPro Tips available that could provide further insight into the company's financial health and market performance. With 14 additional tips listed on InvestingPro, investors can gain a more comprehensive understanding of what to expect from TFFP's stock. To access these tips, visit https://www.investing.com/pro/TFFP and remember to use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.